From its conception in 2009 until today, Bitcoin faced hundreds of collapses that led to proclaiming its death.
Whether it was the collapse that occurred in 2011 due to a failure in a major platform at the time, Mt. Gox, which subsequently went bankrupt and was accused of fraud, or the recent collapse of an FTX that is taking multiple cryptomarket companies by storm, the fact is that the theme is recurrent.
Bitcoin has died in the eyes of analysts hundreds of times in the last decade, dragged down by the maneuvers of companies of questionable integrity, and by the effects of an extremely volatile market.
In fact, a website dedicated to teaching about the crypto-asset, 99 bitcoins, has counted 466 obituaries since 2010.
A number that could certainly be multiplied if publications in all languages are taken into account, but it also gives an idea of the multiple rebirths of a cryptocurrency that has gone through constant bumps since its irruption on the market.
Read more about the so-called deaths of Bitcoin and find the most interesting business news of the day with the Born2invets mobile app.
How to define each Bitcoin death
For the practical purposes of Bitcoin death accounting, the 99 Bitcoins website notes that it uses the following criteria to qualify a statement as an “obituary” of the cryptocurrency: content that explicitly states that Bitcoin is or will be useless, without “maybe” or “could” by means of, and that the content in question is produced by a person with a substantial following, or by a website with high user traffic.
As mentioned above, moreover, the website in question at the moment only posts this content in English, so it can be understood that the string of opinions contrary to the persistence of Bitcoin is much more extensive.
Does this mean that part of the industry has been wrong for more than 10 years? Maybe, but it is also possible that it will end up being right in its doom-and-gloom forecasts over the next few years.
What is certain, however, is that the cryptocurrency’s short life, about to enter its vital adolescence, has been full of upsets that have yet to result in clear, global regulation of its use.
The most shocking Bitcoin deaths
Within this list of symbolic deaths declared about a cryptocurrency that only in the last four years had, in its best moments, a value of more than $57,000 and, in its worst, less than $3,000, some are particularly interesting.
In 2019, for example, financial journalist Ben Walsh noted that “JP Morgan just killed the Bitcoin dream.”
The statement was supported by the fact that the US bank developed and tested a prototype digital currency, but that, for all practical purposes, had zero impact on the cryptocurrency’s price.
Since then, however, the U.S. bank has not substantially changed its reluctant stance on Bitcoin, despite estimating last May that its fair value could be at $38,000. JP Morgan’s experts, in fact, previously pointed out that they were betting more on ether than on the asset created by Satoshi Nakamoto.
Another noteworthy fatal verdict came in 2018, when Paul Donovan, chief economist at UBS, assured that “cryptocurrencies are nearing the end of the road, and it’s time to kill them off.”
“I come to bury bitcoin, not praise it,” Donovan stated in an interview with CNBC. “These things were never going to be currencies. They’re not going to be currencies at any point in the future,” he added.
And for the moment, he is right, but it is well true that its wake is still pending, despite the economist’s certainty at the time.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in finanzas.com, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Jazz Pharmaceuticals’ Leukemia Drug Receives European Commission Approval
Jazz Pharmaceuticals is a biopharmaceutical company dedicated to the development of drugs in neuroscience and oncology. Founded in 2003 in...
Citi Announced a $6 Million Loan to Sempli for SME financing
The credit granted by Citi was given in partnership with high-impact investors and multilateral development organizations. They all seek to...
How Will the Price of Ripple and Cardano Develop in the Next Few Days
The BOLL indicator shows no specific pattern and denotes the support price of $0.4969 and the resistance price of $0.5059,...
RADEEF: a 182 Million Dirham Plan to Combat Flooding in Morocco
RADEEF is also planning major expansion projects. Firstly, it plans to launch work on extending the wastewater treatment plant. The...
How Institutional Investors Feel About Impact Investing
Investors continue to face greenwashing when implementing impact investing. Among their key concerns are misleading or exaggerated impact claims (60%),...
Biotech1 week ago
Vertex Obtains EMA Validation to Expand Indications for Kaftrio
Crowdfunding2 weeks ago
58 Crowdinvesting Platforms Authorized Under the New Regulation in Europe
Biotech6 days ago
Novo Nordisk Plans to Open a Tech Headquarters in Spain
Africa2 weeks ago
Morocco’s Bank Liquidity Deficit Seems to Stabilize